Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
作者信息
Kosar Lynette, Jin Margaret, Kamrul Rejina, Schuster Brenda
机构信息
RxFiles Academic Detailing Program, Saskatoon Health Region, Saskatoon, SK.
出版信息
Can Fam Physician. 2012 Aug;58(8):850-8.
Abstract
摘要
相似文献
1
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.心房颤动的口服抗凝治疗：平衡卒中风险与出血风险。
Can Fam Physician. 2012 Aug;58(8):850-8.
2
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.新型口服抗凝剂用于心房颤动患者的疗效及安全性比较
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.
3
[Differential therapy with the new anticoagulants, 5].[新型抗凝剂的差异疗法，5]
MMW Fortschr Med. 2013 May 16;155(9):20. doi: 10.1007/s15006-013-0676-8.
4
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.新型口服抗凝剂（达比加群、利伐沙班、阿哌沙班）与华法林治疗心房颤动患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24.
5
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.达比加群、利伐沙班和阿哌沙班治疗心房颤动的间接比较。
Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28.
6
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.用于心房颤动患者预防卒中的新型口服抗凝药。
Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006.
7
Anticoagulation in atrial fibrillation.心房颤动的抗凝治疗。
BMJ. 2014 Apr 14;348:g2116. doi: 10.1136/bmj.g2116.
8
[Gastrointestinal bleeding under treatment with new oral anticoagulants].新型口服抗凝剂治疗下的胃肠道出血
MMW Fortschr Med. 2014 Feb 6;156(2):50-2. doi: 10.1007/s15006-014-2599-4.
9
[Stroke risk--atrial fibrillation].
MMW Fortschr Med. 2012 Nov 1;154(19):53-6. doi: 10.1007/s15006-012-1346-y.
引用本文的文献
1
Warfarin: its highs and lows.华法林：其利弊
Can Fam Physician. 2013 Aug;59(8):856-60.
2
Rate versus rhythm control in atrial fibrillation.心房颤动的心率控制与节律控制
Can Fam Physician. 2013 Feb;59(2):161-8.
3
Quality, accountability, and transparency.质量、问责制与透明度。
Can Fam Physician. 2012 Oct;58(10):1084.
4
Canadian trial data?加拿大的试验数据？
Can Fam Physician. 2012 Oct;58(10):1081-2; author reply 1082-3.
本文引用的文献
1
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study.华法林在房颤患者中的净临床获益：来自瑞典房颤队列研究的报告。
Circulation. 2012 May 15;125(19):2298-307. doi: 10.1161/CIRCULATIONAHA.111.055079. Epub 2012 Apr 18.
2
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.新型口服抗凝药物在心房颤动和急性冠状动脉综合征中的应用：ESC 血栓形成工作组-心脏病学抗凝工作组立场文件。
J Am Coll Cardiol. 2012 Apr 17;59(16):1413-25. doi: 10.1016/j.jacc.2012.02.008.
3
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.CHA2DS2-VASc 评分在 CHADS2 评分为 0-1 的房颤患者中对卒中风险分层的价值：一项全国性队列研究。
Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3.
4
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.加拿大心血管学会 2012 年心房颤动指南重点更新：卒中预防和节律/心率控制推荐。
Can J Cardiol. 2012 Mar-Apr;28(2):125-36. doi: 10.1016/j.cjca.2012.01.021.
5
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.心房颤动的抗血栓治疗：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e531S-e575S. doi: 10.1378/chest.11-2304.
6
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.基于证据的抗凝治疗管理：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295.
7
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
8
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
9
Apixaban with antiplatelet therapy after acute coronary syndrome.急性冠脉综合征后应用阿哌沙班联合抗血小板治疗。
N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.
10
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.2011年美国心脏病学会基金会/美国心脏协会/心律学会关于心房颤动患者管理的重点更新（达比加群更新）：美国心脏病学会基金会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2011 Mar 15;57(11):1330-7. doi: 10.1016/j.jacc.2011.01.010. Epub 2011 Feb 14.
Zotero 插件